Blindsided by a change made without consultation
In the long arc of building a knowledge economy, few decisions carry more consequence than how a nation chooses to sustain the work that cannot yet sustain itself. Australia's biotech sector — representing 350,000 workers and nearly 3,000 organisations — has formally appealed to Treasurer Jim Chalmers to reconsider R&D tax incentive changes that, in the industry's view, misread the fundamental economics of medical discovery. When the average journey from laboratory to patient spans 17 years, the question of where companies choose to run their clinical trials is not a minor administrative matter — it is a question about where the future of medicine gets made.
- Nine biotech firms have formally petitioned the Treasurer, warning that restricting the refundable R&D offset could tip the scales toward offshore clinical development at a critical moment for the sector.
- The sting runs deeper than the policy itself — industry leaders say they were given no warning and no consultation, despite years of collaborative engagement with successive governments.
- Treasury insists the changes will improve productivity, but the sector argues that abstract fiscal logic collides badly with the concrete reality of companies managing decade-long cash runways.
- With Treasurer Chalmers yet to respond, companies weighing where to run their next trial — Melbourne or Boston — are already making decisions in the shadow of this uncertainty.
- The stakes extend well beyond tax brackets: if the incentive erodes, so too may the broader ecosystem of researchers, manufacturers, and support services that depend on a viable domestic biotech industry.
Australia's biotech and health technology sector has raised a formal alarm over changes to the research and development tax incentive tucked inside the latest federal budget. Nine companies have petitioned Treasurer Jim Chalmers directly, warning that proposed limits to a refundable offset mechanism — designed to help younger firms manage R&D costs before they turn a profit — could push critical innovation work to other countries.
The concern is rooted in a basic but often overlooked reality: bringing a medical discovery to market takes an average of 17 years, a timeline confirmed by both the National Health and Medical Research Strategy and the Department of Industry, Sciences and Resources. The refundable offset was built precisely to sustain companies through those long, expensive years. Restrict it, and the calculus of where to run a clinical trial shifts — quietly but consequentially.
AusBiotech CEO Rebekah Cassidy captured the sector's frustration plainly: the changes arrived without consultation, despite what she described as a longstanding and collaborative relationship between industry and government. The sector is not a peripheral concern — it supports more than 350,000 jobs across nearly 3,000 organisations nationwide.
Treasury Secretary Jenny Wilkinson has defended the changes as a productivity measure, but the industry's worry is not theoretical. It is about companies with limited cash and long runways making real decisions about where to invest. If Australia offers one fewer reason to choose Melbourne over Boston, some will choose Boston.
The Treasurer's office has not yet responded. What follows will reveal whether the government is prepared to revisit a decision the sector believes was made without fully understanding the industry it affects — and whether Australia intends to remain a place where life-saving medicine can be developed from start to finish.
Australia's biotech and health technology companies are sounding an alarm about changes to the research and development tax incentive buried in the latest federal budget. Nine firms have formally petitioned Treasurer Jim Chalmers, warning that limits to a refundable offset mechanism—designed to help younger, less-established companies offset their R&D costs—could push innovation work offshore and undermine decades of collaborative work between industry and government.
The concern centers on a simple but crucial fact: bringing a medical discovery from the laboratory to a patient's bedside takes time. A lot of time. The National Health and Medical Research Strategy Issues paper from 2025 averaged the timeline at 17 years. The Department of Industry, Sciences and Resources describes it as a decades-long process. Clinical trials must be conducted. Regulators must be satisfied. Markets must be navigated. This is not a theoretical problem or an edge case—it is the baseline reality of how modern medicine gets made. The refundable offset, which allows companies to either reduce their tax bill or receive a direct cash refund based on eligible R&D spending, was built with this reality in mind. It was meant to sustain companies through those long, expensive years before they could turn a profit.
Rebekah Cassidy, CEO of AusBiotech, made the frustration plain. The proposed changes, she said, are already creating uncertainty for Australian companies trying to make long-range decisions about where to conduct clinical development. What stung most was the lack of warning. "Our sector has had a longstanding, collaborative working relationship with governments, so we were blindsided by this proposed change which occurred with no consultation," she said. The biotech sector is not a niche concern—it supports more than 350,000 jobs across almost 3,000 organisations across the country. Restrict the incentive, and you risk not just the companies themselves but the entire ecosystem of researchers, manufacturers, and support services that depend on them.
Treasury Secretary Jenny Wilkinson has argued that the R&D tax incentive changes will provide a productivity boost. The logic, presumably, is that tightening the mechanism will improve fiscal discipline or redirect resources more efficiently. But the sector's concern is not about abstract economic theory—it is about the concrete decision-making of companies with limited cash and long runways. If the refundable offset shrinks, a company deciding whether to run its next clinical trial in Melbourne or Boston will have one fewer reason to choose Melbourne. The money matters. The timeline matters more.
Treasurer Chalmers' office has not yet responded to requests for comment. What happens next depends on whether the government is willing to revisit a decision that, from the industry's perspective, was made without understanding the sector it affects. The stakes are not just about tax policy or budget arithmetic. They are about whether Australia remains a place where life-saving discoveries can be developed, or whether that work migrates to countries with more patient capital and longer time horizons.
Citas Notables
Our sector has had a longstanding, collaborative working relationship with governments, so we were blindsided by this proposed change which occurred with no consultation.— Rebekah Cassidy, CEO of AusBiotech
It is well understood by industry and government that bringing these critical health products to market routinely takes well beyond a decade.— Rebekah Cassidy, CEO of AusBiotech
La Conversación del Hearth Otra perspectiva de la historia
Why does the timeline matter so much here? Couldn't companies just absorb the cost?
Because seventeen years is not a sprint. A company burns through cash for nearly two decades before it sees revenue. The refundable offset is what keeps the lights on during that period. Without it, you need either massive upfront capital or you need to find it elsewhere—which often means another country.
But Treasury says this will boost productivity. Doesn't tightening incentives force companies to be more efficient?
That's the theory. But efficiency doesn't speed up clinical trials or regulatory approval. You can't innovate faster by having less money. What you can do is move your operation to a place that will fund you.
So this is really about capital flight?
It's about where companies choose to invest. If Australia makes it harder to fund R&D here, companies will fund it elsewhere. The jobs, the discoveries, the tax revenue—all of it follows the money.
Why wasn't there consultation? That seems like an obvious step.
That's what blindsided the sector. They've worked with government for years. They expected a conversation. Instead they got a budget line item with no warning. It broke trust.
Can the government reverse this?
They can. But they have to decide whether they believe in long-term innovation or short-term budget savings. Those are not the same thing.